FACSIMILE COVER SHEET SALIWANCHIK, LLOYD & SALIWANCHIK

CENTRAL FAX CENTER

A Professional Association P.O. Box 142950 Gainesville, FL 32614-2950 APR 0 2 2007

RECEIVED

Telephone (52) 375-8100 Facsimile (352) 372-5800

TO: U.S. Patent Office,

FROM: Margaret Efron

FAX NO.:

(571) 273-8300

DATE: April 2, 2007

NO. OF PAGES

(INCLUDING COVER SHEET):

11

SUBJECT/MESSAGE:

Serial No. 10/588,749; filed August 7, 2006 Attorney Docket No. UF-270C3

Preliminary Amendment (10 pages) 1.

THIS IS AN OFFICIAL DOCUMENT!

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named below. This message may be an attorney-client communication, and as such is privileged und confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.

If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.

RECEIVED CENTRAL FAX CENTER

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below:

April 2, 2007

Margaret Efron, Patent Attorney

COMMUNICATION APR 0 2 2007
Examining Group Not yet assigned
Patent Application
Docket No. UF-270C3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Richard J. Melker et al.

Serial No.

10/588,749

Biled

August 7, 2006

For

System and Method for Real-Time Diagnosis, Treatment, and

Therapeutic Drug Monitoring

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT UNDER 37 CFR §1.115

Sir:

Please amend the above-identified patent application as follows:

Amendment to the Specification begins on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper.

Remarks/Arguments follow the amendment sections of this paper.